Table 2 Differences in activation between 15 participants at clinical high risk for psychosis (CHR) receiving placebo, 19 healthy controls and 15 CHR participants receiving cannabidiol (CBD).

From: A single dose of cannabidiol modulates medial temporal and striatal function during fear processing in people at clinical high risk for psychosis

Region

Talairach coordinates

Cluster size, no. of voxels

p Valuea

x

y

z

Differences between healthy controls and CHR-placebo

Placebo > controls

 Parahippocampal gyrus

−18

−33

−13

5

0.002

 Parahippocampal gyrus

−25

−44

−7

35

<0.001

 Parahippocampal gyrus

18

−33

−3

22

<0.001

 Lingual gyrus

−22

−56

3

5

0.003

Controls > placebo

 Putamen

−22

11

0

5

0.002

 Caudate head

−11

19

0

10

<0.001

 Putamen

25

11

3

7

0.001

 Putamen

22

15

0

13

<0.001

Differences between CHR-placebo and CHR-CBD

Placebo > CBD

 Amygdala

−25

−4

−16

4

0.002

 Parahippocampal gyrus

−18

−56

−7

11

<0.001

CBD > placebo

 Putamen

25

15

0

6

0.001

 Putamen

−18

11

7

16

<0.001

  1. aCorrected for <1 false-positive cluster.